Back to search

Boston University

Therapeutic TAC-nology & targeted drug delivery for precision medicines

Abstract

dc:description.abstract

Therapeutics that harness induced proximity between biomolecules are emerging as transformative tools in biological engineering and precision medicine. By spatially controlling molecular interactions, these approaches enable selective degradation, stabilization, relocalization, or functional modulation of disease-associated proteins. This dissertation introduces three novel strategies and platforms that expand the capabilities of proximity-based therapeutics and drug delivery systems, with applications ranging from oncology and viral infections to fundamental tool development. First, a modular protein degradation system is developed using midnolin, a recently identified proteasomal adaptor that operates via a unique ubiquitin-independent mechanism. By fusing proteasomal binding motifs of midnolin to synthetic binding domains, we create synthetic midnolin (Syn-MIDN) constructs that enable ubiquitin-independent, proteasome-mediated degradation of non-native intracellular target proteins. This system demonstrates programmable activity against diverse model targets and oncogenic transcription factors spanning various subcellular localizations and reveals mechanistic flexibility in how proximity-induced degradation can be achieved beyond canonical pathways. Extending this concept to therapeutic selectivity, a new therapeutic modality termed antibody-RIPTAC conjugates (ARCs) is engineered to induce dual-logic cytotoxicity for oncology applications. These bioconjugates require the co-expression of both an intracellular and extracellular protein to trigger cell death, offering unprecedented selectivity in targeting cancer cells while sparing healthy tissue. We validate this approach in proof-of-concept cell models and large -omics datasets identify actionable therapeutic axes priming this modality for therapeutic development. In a separate effort targeting infectious disease, a nanoparticle-based delivery system is designed to direct antiviral agents to pulmonary tissue and endolysosomal compartments—key sites for viral entry and replication. Biodegradable polymeric nanoparticles loaded with mefloquine achieve lysosomal localization and inhibit infection and spread of multiple coronaviruses, including multiple murine and human coronavirus strains such as the SARS-CoV-2 Omicron variant. This platform demonstrates efficacy in both prophylactic and post-exposure settings, offering a versatile approach for broad-spectrum antiviral therapy and rapid pandemic response. Together, these efforts represent significant advances in therapeutic engineering, spanning synthetic biology, chemical biology, and nanomedicine. By expanding the toolkit for induced proximity and improving site-specific drug delivery, this work lays the foundation for novel therapeutics capable of targeting previously undruggable proteins, implementing complex logic-gated cytotoxicity, and combating viral diseases through precision pulmonary delivery.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Biomedical Engineering
Grantor
Boston University
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Tingley, Brett Michael
Advisor dc:contributor.advisor
  • Grinstaff, Mark W.
ORCID dc:identifier.orcid

Subjects

dc:subject × 7

Rights

dc:rights
Statement dc:rights
  • Attribution 4.0 International
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/51135

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Tingley, Brett Michael. Therapeutic TAC-nology & targeted drug delivery for precision medicines. doctoral thesis, Boston University, 2025. https://hdl.handle.net/2144/51135